Folger Nolan Fleming Douglas Capital Management Inc. trimmed its position in Bristol-Myers Squibb Company (NYSE:BMY) by 0.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 17,113 shares of the biopharmaceutical company’s stock after selling 46 shares during the quarter. Folger Nolan Fleming Douglas Capital Management Inc.’s holdings in Bristol-Myers Squibb were worth $954,000 as of its most recent SEC filing.
Other hedge funds also recently made changes to their positions in the company. First Trust Advisors LP raised its position in Bristol-Myers Squibb by 10.7% during the second quarter. First Trust Advisors LP now owns 433,050 shares of the biopharmaceutical company’s stock valued at $24,130,000 after acquiring an additional 41,892 shares in the last quarter. Toronto Dominion Bank grew its holdings in Bristol-Myers Squibb by 54.0% in the first quarter. Toronto Dominion Bank now owns 464,591 shares of the biopharmaceutical company’s stock valued at $25,264,000 after purchasing an additional 162,884 shares during the period. Mutual of America Capital Management LLC grew its holdings in Bristol-Myers Squibb by 1.9% in the first quarter. Mutual of America Capital Management LLC now owns 201,037 shares of the biopharmaceutical company’s stock valued at $10,932,000 after purchasing an additional 3,833 shares during the period. Dividend Assets Capital LLC acquired a new stake in Bristol-Myers Squibb in the second quarter valued at approximately $737,000. Finally, Quantitative Investment Management LLC acquired a new stake in Bristol-Myers Squibb in the first quarter valued at approximately $6,150,000. Institutional investors own 69.82% of the company’s stock.
Shares of Bristol-Myers Squibb Company (NYSE:BMY) opened at $62.02 on Wednesday. Bristol-Myers Squibb Company has a 1 year low of $46.01 and a 1 year high of $66.10. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $102,244.66, a price-to-earnings ratio of 21.10, a price-to-earnings-growth ratio of 2.37 and a beta of 1.18.
Several analysts have commented on the company. Credit Suisse Group set a $58.00 price objective on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Wednesday, August 16th. Citigroup set a $72.00 price target on Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Tuesday. Goldman Sachs Group reaffirmed a “buy” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a research note on Wednesday, August 9th. Cowen reaffirmed a “hold” rating and issued a $65.00 price target on shares of Bristol-Myers Squibb in a research note on Tuesday, September 19th. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $72.00 price target on shares of Bristol-Myers Squibb in a research note on Wednesday, September 27th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company. Bristol-Myers Squibb currently has an average rating of “Hold” and an average target price of $64.93.
In other Bristol-Myers Squibb news, EVP Sandra Leung sold 156,582 shares of Bristol-Myers Squibb stock in a transaction on Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the sale, the executive vice president now owns 584,373 shares in the company, valued at $37,031,717.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.23% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: “Bristol-Myers Squibb Company (BMY) Shares Sold by Folger Nolan Fleming Douglas Capital Management Inc.” was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.chaffeybreeze.com/2017/12/06/bristol-myers-squibb-company-bmy-shares-sold-by-folger-nolan-fleming-douglas-capital-management-inc.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.